Restrictions on the use of higher cost drugs for rheumatoid arthritis in England: Surveys of Clinical Commissioning Groups; prescribers

被引：2
|
作者：
Walker, David [1 ]
Barry, Jane [2 ]
Akroyd, Laura [2 ]
Robinson, Sandra [1 ]
机构：
[1] Northumbria Healthcare NHS Fdn Trust, Res & Dev, North Shields, England
[2] Ireland Galapagos Biotech, Med Affairs Dept, Cambridge, England
来源：
MUSCULOSKELETAL CARE | 2023年 / 21卷 / 03期
关键词：
D O I：
10.1002/msc.1767
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：943 / 946
页数：4
相关论文
共 22 条
  • [1] INEQUITY IN CLINICAL COMMISSIONING GROUP FUNDING ACROSS ENGLAND FOR HIGH-COST BIOLOGIC DRUGS IN RHEUMATOID ARTHRITIS
    Buckeldee, Olivia
    Khanna, Rajakshi
    Snell, Laura
    Attipoe, Laura
    RHEUMATOLOGY, 2023, 62
  • [2] RESTRICTION OF USE OF HIGH COST DRUGS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS BY CCGS IN ENGLAND
    Walker, David
    Robinson, Sandra
    Barry, Jane
    Punter, Phillip
    Kearns, Sinead
    RHEUMATOLOGY, 2021, 60 : 77 - 77
  • [3] P142 Restriction of use of high cost drugs for the treatment of rheumatoid arthritis by CCGs in England
    Walker, David
    Robinson, Sandra
    Barry, Jane
    Punter, Phillip
    Kearns, Sinead
    RHEUMATOLOGY, 2021, 60
  • [4] Cost Sharing, Family Health Care Burden, and the Use of Specialty Drugs for Rheumatoid Arthritis
    Karaca-Mandic, Pinar
    Joyce, Geoffrey F.
    Goldman, Dana P.
    Laouri, Marianne
    HEALTH SERVICES RESEARCH, 2010, 45 (05) : 1227 - 1250
  • [5] Uptake of Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in a Single Clinical Commissioning Group in England Without Restrictions to Their Use
    Kristina Medlinskiene
    Matthew Fay
    Duncan Petty
    Clinical Drug Investigation, 2019, 39 : 401 - 405
  • [6] Uptake of Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in a Single Clinical Commissioning Group in England Without Restrictions to Their Use
    Medlinskiene, Kristina
    Fay, Matthew
    Petty, Duncan
    CLINICAL DRUG INVESTIGATION, 2019, 39 (04) : 401 - 405
  • [7] Economic Benefit of Sponsored Controlled Clinical Trials: The Avoidable Cost in Drugs for the Treatment of Rheumatoid Arthritis
    Liberman, Federico
    Elgart, Jorge
    Strusberg, Ingrid
    VALUE IN HEALTH REGIONAL ISSUES, 2019, 20 : 7 - 11
  • [8] Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: Clinical evaluation and cost analysis
    Aletaha, D
    Smolen, JS
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (02): : 181 - 188
  • [9] Cost-effectiveness of Biological Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis: Implications for Clinical Practice
    Kuijper, T. Martijn
    Buisman, Leander R.
    Hazes, Johanna M.
    Weel, Angelique E.
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (07) : 965 - 967
  • [10] The use of lipid-lowering drugs across ethnic groups in the secondary prevention of ischaemic heart disease: analysis of cross-sectional surveys in England
    Gill, PS
    Quirke, TP
    Mant, JW
    Allan, TF
    BRITISH JOURNAL OF GENERAL PRACTICE, 2004, 54 (503): : 442 - 443
123